These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11426651)

  • 1. Potential roles of antisense technology in cancer chemotherapy.
    Crooke ST
    Oncogene; 2000 Dec; 19(56):6651-9. PubMed ID: 11426651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D; Lahn M
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense DNAs as targeted therapeutics for cancer: no longer a dream.
    Cho-Chung YS
    Curr Opin Investig Drugs; 2002 Jun; 3(6):934-9. PubMed ID: 12137417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: LErafAON, NeoPharm.
    Moreira JN; Simões S
    Curr Opin Mol Ther; 2003 Oct; 5(5):547-52. PubMed ID: 14601525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology evaluation: leukemia therapy, University of Pennsylvania.
    Orr RM
    Curr Opin Mol Ther; 1999 Jun; 1(3):399-403. PubMed ID: 11713805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides as therapeutic agents.
    Galderisi U; Cascino A; Giordano A
    J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antisense targeting in neurology].
    Tellería-Díaz A
    Rev Neurol; 2000 Oct 16-31; 31(8):762-9. PubMed ID: 11082887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
    Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology evaluation: CpG-7909, Coley.
    Paul S
    Curr Opin Mol Ther; 2003 Oct; 5(5):553-9. PubMed ID: 14601526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GTI-2040. Lorus Therapeutics.
    Orr RM
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ISIS-3521. Isis Pharmaceuticals.
    Li K; Zhang J
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Hoffman RM
    Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.